Adoptive cellular immunotherapy for childhood malignancies

Bone Marrow Transplantation

Volumn 41, Issue 2, 2008, Pages 183-192

  Cooper, L J N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CHIMERIC PROTEIN; EPSTEIN BARR VIRUS ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; LATENT MEMBRANE PROTEIN 1; LATENT MEMBRANE PROTEIN 2; LENTIVIRUS VECTOR; OKT 3; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TUMOR ANTIGEN;

ADENOVIRUS; ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ASPERGILLOSIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHILDHOOD CANCER; CLINICAL TRIAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; EPSTEIN BARR VIRUS; FOLLICULAR LYMPHOMA; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LYMPHOCYTE CLONE; LYMPHOCYTE DEPLETION; LYMPHOPROLIFERATIVE DISEASE; MELANOMA; PRIORITY JOURNAL; REVIEW; SUICIDE GENE; VIRAL GENE DELIVERY SYSTEM; VIRUS INFECTION;

CHILD; HUMANS; IMMUNOTHERAPY, ADOPTIVE; NEOPLASMS; T-LYMPHOCYTES; VIRUS DISEASES;

EID: 38849083905     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705930     Document Type: Review

References (140)

1. Blaauwbroek R, Groenier K, Kamps W, Meyboom-de Jong B, Postma A. Late effects in adult survivors of childhood cancer: The need for life-long follow-up. Ann Oncol 2007; e-pub ahead of print.
2. Geenen MM, Cardous-Ubbink MC, Kremer LC, van den Bos C, van der Pal HJ, Heinen RC et al. Medical assessment of adverse health outcomes in long-term survivors of childhood cancer. JAMA 2007; 297: 2705-2715.
3. Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows AT et al. Childhood Cancer Survivor Study. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006; 355 1572-1582.
4. Foster AE, Rooney CM. Improving T cell therapy for cancer. Expert Opin Biol Ther 2006; 6: 215-229.
5. Greenberg PD, Riddell SR. Deficient cellular immunity-finding and fixing the defects. Science 1999; 285: 546-551.
6. June CH. Adoptive T cell therapy for cancer in the clinic. J Clin Invest 2007; 117: 1466-1476.
7. Gattinoni L, Powell Jr DJ, Rosenberg SA, Restifo NP. Adoptive immunotherapy for cancer: Building on success. Nat Rev Immunol 2006; 6: 383-393.
8. Rosenberg SA. Shedding light on immunotherapy for cancer. N Engl J Med 2004; 350: 1461-1463.
9. Leen AM, Rooney CM, Foster AE. Improving T cell therapy for cancer. Annu Rev Immunol 2007; 25: 243-265.
10. Billingham R, Brent L, Medawar P. Quantitative studies on tissue transplantation immunity: The origin, strength and duration of actively and adoptively acquired immunity. Proc R Soc Biol 1954; 143: 58-80.
11. Schleuning M. Adoptive allogeneic immunotherapy-history and future perspectives. Transfus Sci 2000; 23: 133-150.
12. Barnes DWH, Loutit JF. Treatment of murine leukaemia with x-rays and homologous bone marrow: II. Br J Haematol 1957; 3: 241-252.
13. Brunschwig A, Southam CM, Levin AG. Host resistance to cancer. Clinical experiments by homotransplants, autotransplants and admixture of autologous leucocytes. Ann Surg 1965; 162: 416-425.
14. Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD et al. Restoration of viral immunity in immunodedeficient humans by the adoptive transfer of T cell clones. Science 1992; 257: 238-241.
15. Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995; 333: 1038-1044.
16. Peggs KS, Verfuerth S, Pizzey A, Khan N, Guiver M, Moss PA et al. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet 2003; 362: 1375-1377.
17. Khanna R, Bell S, Sherritt M, Galbraith A, Burrows SR, Rafter L et al Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc Natl Acad Sci USA 1999; 96 10391-10396.
18. Cho HI, Hong YS, Lee MA, Kim EK, Yoon SH, Kim CC et al. Adoptive transfer of Epstein-Barr virus-specific cytotoxic T-lymphocytes for the treatment of angiocentric lymphomas. Int J Hematol 2006; 83: 66-73.
19. Pakakasama S, Eames GM, Morriss MC, Huls MH, Rooney CM, Heslop HE et al. Treatment of Epstein-Barr virus lymphoproliferative disease after hematopoietic stem-cell transplantation with hydroxyurea and cytotoxic T-cell lymphocytes. Transplantation 2004; 78: 755-757.
20. Gottschalk S, Bollard CM, Straathof KC, Louis CU, Savoldo B, Dotti G et al. T cell therapies. Ernst Schering Found Symp Proc 2006; 4: 69-82.
21. Savoldo B, Goss JA, Hammer MM, Zhang L, Lopez T, Gee AP et al. Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood 2006; 108: 2942-2949.
22. Gottschalk S, Rooney CM, Heslop HE. Post-transplant lymphoproliferative disorders. Annu Rev Med 2005; 56: 29-44.
23. Sun Q, Burton R, Reddy V, Lucas KG. Safety of allogeneic Epstein-Barr virus (EBV)-speci.c cytotoxic T lymphocytes for patients with refractory EBV-related lymphoma. Br J Haematol 2002; 118: 799-808.
24. Rooney CM, Smith CA, Ng CY, Loftin SK, Sixbey JW, Gan Y et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998; 92: 1549-1555.
25. Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat Rev Cancer 2004; 4: 757-768.
26. Bollard CM, Heslop HE, Brenner MK. Gene-marking studies of hematopoietic cells. Int J Hematol 2001; 73: 14-22.
27. Heslop HE, Ng CY, Li C, Smith CA, Loftin SK, Krance RA et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of genemodified virus-specific T lymphocytes. Nat Med 1996; 2: 551-555.
28. Dupont J, Latouche JB, Ma C, Sadelain M. Artificial antigen-presenting cells transduced with telomerase efficiently expand epitope-specific, human leukocyte antigen-restricted cytotoxic T cells. Cancer Res 2005; 65: 5417-5427.
29. Schilbach K, Kerst G, Walter S, Eyrich M, Wernet D, Handgretinger R et al. Cytotoxic minor histocompatibility antigen HA-1-speci.c CD8+ effector memory T cells: Artificial APCs pave the way for clinical application by potent primary in vitro induction. Blood 2005; 106: 144-149.
30. Oelke M, Maus MV, Didiano D, June CH, Mackensen A, Schneck JP et al Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells. Nat Med 2003; 9: 619-624.
31. Latouche JB, Sadelain M. Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells. Nat Biotechnol 2000; 18 405-409.
32. Hirano N, Butler MO, Xia Z, Berezovskaya A, Murray AP, Ansen S et al Efficient presentation of naturally processed HLA class I peptides by artificial antigen-presenting cells for the generation of effective antitumor responses. Clin Cancer Res 2006; 12: 2967-2975.
33. Butler MO, Lee JS, Ansen S, Neuberg D, Hodi FS, Murray AP et al. Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell. Clin Cancer Res 2007; 13: 1857-1867.
34. Foster AE, Leen AM, Lee T, Okamura T, Lu A, Vera J et al. Autologous designer antigen-presenting cells by gene modification of T lymphocyte blasts with IL-7 and IL-12. J Immunother (1997) 2007; 30: 506-516.
35. Melenhorst JJ, Solomon SR, Shenoy A, Hensel NF, McCoy Jr JP, Keyvanfar K et al. Robust expansion of viral antigen-specific CD4+ and CD8+ T cells for adoptive T cell therapy using gene-modified activated T cells as antigen presenting cells. J Immunother (1997) 2006; 29: 436-443.
36. Mauri D, Wyss-Coray T, Gallati H, Pichler WJ. Antigen-presenting T cells induce the development of cytotoxic CD4+ T cells. I. Involvement of the CD80-CD28 adhesion molecules. J Immunol 1995; 155: 118-127.
37. Cooper LJ, Al-Kadhimi Z, Serrano LM, Pfeiffer T, Olivares S, Castro A et al. Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1. Blood 2005; 105: 1622-1631.
38. Jurgens LA, Khanna R, Weber J, Orentas RJ. Transduction of primary lymphocytes with Epstein-Barr virus (EBV) latent membrane protein-specific T-cell receptor induces lysis of virus-infected cells: a novel strategy for the treatment of Hodgkin's disease and nasopharyngeal carcinoma. J Clin Immunol 2006; 26: 22-32.
39. Demachi-Okamura A, Ito Y, Akatsuka Y, Tsujimura K, Morishima Y, Takahashi T et al. Epstein-Barr virus (EBV) latent membrane protein-1-specific cytotoxic T lymphocytes targeting EBV-carrying natural killer cell malignancies. Eur J Immunol 2006; 36: 593-602.
40. Straathof KC, Leen AM, Buza EL, Taylor G, Huls MH, Heslop HE et al Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma. J Immunol 2005; 175: 4137-4147.
41. Sing AP, Ambinder RF, Hong DJ, Jensen M, Batten W, Petersdorf E et al Isolation of Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes that lyse Reed-Sternberg cells: Implications for immune-mediated therapy of EBV+ Hodgkin's disease. Blood 1997; 89: 1978-1986.
42. Bollard CM, Gottschalk S, Leen AM, Weiss H, Straathof KC, Carrum G et al. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood 2007; 110: 2838-2845.
43. Lucas KG, Salzman D, Garcia A, Sun Q. Adoptive immunotherapy with allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes for recurrent, EBV-positive Hodgkin disease. Cancer 2004; 100: 1892-1901.
44. Chapman AL, Rickinson AB, Thomas WA, Jarrett RF, Crocker J, Lee SP et al. Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients: Implications for a T-cell-based therapy. Cancer Res 2001; 61: 6219-6226.
45. Rooney CM, Roskrow MA, Suzuki N, Ng CY, Brenner MH, Heslop H. Treatment of relapsed Hodgkin's disease using EBV-specific cytotoxic T cells. Ann Oncol 1998; 9 (Suppl 5): S129-S132.
46. Bollard CM, Aguilar L, Straathof KC, Gahn B, Huls MH, Rousseau A et al. Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. J Exp Med 2004; 200: 1623-1633.
47. Gandhi MK, Wilkie GM, Dua U, Mollee PN, Grimmett K, Williams T et al Immunity, homing and efficacy of allogeneic adoptive immunotherapy for posttransplant lymphoproliferative disorders. Am J Transplant 2007; 7: 1293-1299.
48. Haque T, Wilkie GM, Jones MM, Higgins CD, Urquhart G, Wingate P et al Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: Results of a phase 2 multicenter clinical trial. Blood 2007; 110: 1123-1131.
49. Haque T, Wilkie GM, Taylor C, Amlot P, Murad P, Iley A et al. Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet 2002; 360: 436-442.
50. Karlsson H, Brewin J, Kinnon C, Veys P, Amrolia PJ. Generation of trispecific cytotoxic T cells recognizing cytomegalovirus, adenovirus, and Epstein-Barr virus: An approach for adoptive immunotherapy of multiple pathogens. J Immunother (1997) 2007; 30: 544-556.
51. Leen AM, Myers GD, Sili U, Huls MH, Weiss H, Leung KS et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 2006; 12: 1160-1166.
52. Chatziandreou I, Gilmour KC, McNicol AM, Costabile M, Sinclair J, Cubitt D et al. Capture and generation of adenovirus specific T cells for adoptive immunotherapy. Br J Haematol 2007; 136: 117-126.
53. Feuchtinger T, Lang P, Hamprecht K, Schumm M, Greil J, Jahn G et al Isolation and expansion of human adenovirus-specific CD4+ and CD8+ T cells according to IFN-gamma secretion for adjuvant immunotherapy. Exp Hematol 2004; 32: 282-289.
54. Becker C, Pohla H, Frankenberger B, Schuler T, Assenmacher M, Schendel DJ et al. Adoptive tumor therapy with T lymphocytes enriched through an IFN-gamma capture assay. Nat Med 2001; 7: 1159-1162.
55. Perruccio K, Tosti A, Burchielli E, Topini F, Ruggeri L, Carotti A et al. Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood 2005; 106 4397-4406.
56. Amrolia PJ, Muccioli-Casadei G, Huls H, Adams S, Durett A, Gee A et al. Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haplo-identical stem cell transplantation. Blood 2006; 108: 1797-1808.
57. Guinan EC, Boussiotis VA, Neuberg D, Brennan LL, Hirano N, Nadler LM et al. Transplantation of anergic histoincompatible bone marrow allografts. N Engl J Med 1999; 340: 1704-1714.
58. Reisner Y, Gur H, Reich-Zeliger S, Martelli MF, Bachar-Lustig E. Hematopoietic stem cell transplantation across major genetic barriers: tolerance induction by megadose CD34 cells and other veto cells. Ann NY Acad Sci 2005; 1044: 70-83.
59. Herberman RB, Nunn ME, Lavrin DH. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic acid allogeneic tumors. I. Distribution of reactivity and specificity. Int J Cancer 1975; 16: 216-229.
60. Herberman RB, Nunn ME, Holden HT, Lavrin DH. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells. Int J Cancer 1975; 16: 230-239.
61. Karre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 1986; 319: 675-678.
62. Sentman CL, Barber MA, Barber A, Zhang T. NK cell receptors as tools in cancer immunotherapy. Adv Cancer Res 2006; 95: 249-292.
63. Ruggeri L, Mancusi A, Capanni M, Martelli MF, Velardi A. Exploitation of alloreactive NK cells in adoptive immunotherapy of cancer. Curr Opin Immunol 2005; 17: 211-217.
64. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097-2100.
65. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005; 105: 3051-3057.
66. Ren XB, Yu JP, Cao S, Ren BZ, Li H, Liu H et al. Antitumor effect of large doses IL-2-activated HLA haploidentical peripheral blood stem cells on refractory metastatic solid tumor treatment. Cancer Biother Radiopharm 2007; 22: 223-234.
67. Chung Y, Qin H, Kang CY, Kim S, Kwak LW, Dong C. An NKT-mediated autologous vaccine generates CD4 T-cell dependent potent antilymphoma immunity. Blood 2007; 110: 2013-2019.
68. Seino K, Motohashi S, Fujisawa T, Nakayama T, Taniguchi M. Natural killer T cell-mediated antitumor immune responses and their clinical applications. Cancer Sci 2006; 97: 807-812.
69. Lee PP, Yee C, Savage PA, Fong L, Brockstedt D, Weber JS et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 1999; 5: 677-685.
70. Yee C, Thompson JA, Roche P, Byrd DR, Lee PP, Piepkom M et al. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T cell-mediated vitiligo. J Exp Med 2000; 192: 1637-1644.
71. Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, Celis E et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA 2002; 99: 16168-16173.
72. Wrzesinski C, Paulos CM, Gattinoni L, Palmer DC, Kaiser A, Yu Z et al Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8T cells. J Clin Invest 2007; 117: 492-501.
73. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005; 23: 2346-2357.
74. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ et al. Cancer regression and auto-immunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298: 850-854.
75. Dudley ME, Wunderlich JR, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL et al. A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother (1997) 2002; 25 243-251.
76. Powell Jr DJ, Dudley ME, Robbins PF, Rosenberg SA. Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. Blood 2005; 105: 241-250.
77. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM et al. Cancer regression patients after transfer of genetically engineered lymphocytes. Science 2006; 314: 126-129.
78. Eshhar Z. Tumor-specic T-bodies: Towards clinical application. Cancer Immunol Immunother 1997; 45: 131-136.
79. Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 2006; 12: 6106-6115.
80. Mitsuyasu RT, Anton AP, Deeks SG, Scadden DT, Connick E, Downs MT et al. Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta genemodified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects. Blood 2000; 96 785-793.
81. Walker RE, Bechtel CM, Natarajan V, Baseler M, Hege KM, Metcalf JA et al. Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immuno-deficiency virus infection. Blood 2000; 96: 467-474.
82. Lamers CH, Langeveld SC, Groot-van Ruijven CM, Debets R, Sleijfer S, Gratama JW. Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo. Cancer Immunol Immunother 2007; 56: 1875-1883.
83. Lamers CH, Sleijfer S, Vulto AG, Kruit WH, Kliffen M, Debets R et al Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol 2006; 24: E20-e22.
84. Jensen MC, Popplewell L, DiGiusto DL, Kalos M, Cooper LJN, Raubitschek A et al. A first-in-human clinical trial of adoptive therapy using CD19-specific chimeric antigen receptor re-directed T cells for recurrent/refractory follicular lymphoma. Mol Ther 2007; 15: S142.
85. Levine BL, Humeau LM, Boyer J, MacGregor RR, Rebello T, Lu X et al Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci USA 2006; 103: 17372-17377.
86. Huang X, Wilber AC, Bao L, Tuong D, Tolar J, Orchard PJ et al. Stable gene transfer and expression in human primary T cells by the Sleeping Beauty transposon system. Blood 2006; 107: 483-491.
87. Frommolt R, Rohrbach F, Theobald M. Sleeping Beauty transposon system - future trend in T-cell-based gene therapies? Future Oncol 2006; 2: 345-349.
88. Numbenjapon T, Serrano LM, Chang WC, Forman SJ, Jensen MC, Cooper LJ. Antigen-independent and antigen-dependent methods to numerically expand CD19-specific CD8+ T cells. Exp Hematol 2007; 35: 1083-1090.
89. Numbenjapon T, Serrano LM, Singh H, Kowolik CM, Olivares S, Gonzalez N et al. Characterization of an artificial antigen-presenting cell to propagate cytolytic CD19-specific T cells. Leukemia 2006; 20 1889-1892.
90. Ahmed N, Ratnayake M, Savoldo B, Perlaky L, Dotti G, Wels WS et al Regression of experimental medulloblastoma following transfer of HER2-specific T cells. Cancer Res 2007; 67: 5957-5964.
91. Savoldo B, Rooney CM, Di Stasi A, Abken H, Hombach A, Foster AE et al Epstein barr virus-specific cytotoxic T lymphocytes expressing the anti-CD30{zeta} artificial chimeric T-cell receptor for immunotherapy of Hodgkin's disease. Blood 2007; 110: 2620-2630.
92. Park JR, Digiusto DL, Slovak M, Wright C, Naranjo A, Wagner J et al Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther 2007; 15: 825-833.
93. Gonzalez S, Naranjo A, Serrano LM, Chang WC, Wright CL, Jensen MC et al. Genetic engineering of cytolytic T lymphocytes for adoptive T-cell therapy of neuroblastoma. J Gene Med 2004; 6: 704-711.
94. Jorritsma A, Gomez-Eerland R, Dokter M, van de Kasteele W, Zoet YM, Doxiadis II et al. Selecting highly affine and well expressed TCRs for gene therapy of melanoma. Blood 2007; e-pub ahead of print.
95. Cooper LJ, Kalos M, Lewinsohn DA, Riddell SR, Greenberg PD. Transfer of specificity for human immunodeficiency virus type 1 into primary human T lymphocytes by introduction of T-cell receptor genes. J Virol 2000; 74: 8207-8212.
96. Stauss HJ, Thomas S, Cesco-Gaspere M, Hart DP, Xue SA, Holler A et al WT1-specific T cell receptor gene therapy: Improving TCR function in transduced T cells. Blood Cells Mol Dis 2007; e-pub ahead of print.
97. Thomas S, Hart DP, Xue SA, Cesco-Gaspere M, Stauss HJ. T-cell receptor gene therapy for cancer: The progress to date and future objectives. Expert Opin Biol Ther 2007; 7: 1207-1218.
98. Spaapen R, van den Oudenalder K, Ivanov R, Bloem A, Lokhorst H, Mutis T et al. Rebuilding human leukocyte antigen class II-restricted minor histocompatibility antigen specificity in recall antigen-specific T cells by adoptive T cell receptor transfer: Implications for adoptive immunotherapy. Clin Cancer Res 2007; 13: 4009-4015.
99. Heemskerk MH, Hagedoorn RS, van der Hoorn MA, van der Veken LT, Hoogeboom M, Kester MG et al. Efficiency of T-cell receptor expression in dual-specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex. Blood 2007; 109: 235-243.
100. Mommaas B, van Halteren AG, Pool J, van der Veken L, Wieles B, Heemskerk MH et al. Adult and cord blood T cells can acquire HA-1 specificity through HA-1 T-cell receptor gene transfer. Haematologica 2005; 90: 1415-1421.
101. Cohen CJ, Li YF, El-Gamil M, Robbins PF, Rosenberg SA, Morgan RA et al. Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. Cancer Res 2007; 67: 3898-3903.
102. Cohen CJ, Zhao Y, Zheng Z, Rosenberg SA, Morgan RA. Enhanced antitumor activity of murine-human hybrid T-Cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. Cancer Res 2006; 66: 8878-8886.
103. Kuball J, Dossett ML, Wolfl M, Ho WY, Voss RH, Fowler C et al. Facilitating matched pairing and expression of TCR chains introduced into human T cells. Blood 2007; 109: 2331-2338.
104. Stauss HJ, Cesco-Gaspere M, Thomas S, Hart DP, Xue SA, Holler A et al Monoclonal T-cell receptors: New reagents for cancer therapy. Mol Ther 2007; 15: 1744-1750.
105. Kowolik CM, Topp MS, Gonzalez S, Pfeiffer T, Olivares S, Gonzalez N et al. CD28 costimulation provided through a CD19-speci.c chimeric antigen receptor enhances in vivo persistence and antitumor ef.cacy of adoptively transferred T cells. Cancer Res 2006; 66: 10995-11004.
106. Pule MA, Straathof KC, Dotti G, Heslop HE, Rooney CM, Brenner MK. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther 2005; 12: 933-941.
107. Maher J, Brentjens RJ, Gunset G, Riviere I, Sadelain M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ/CD28 receptor. Nat Biotechnol 2002; 20: 70-75.
108. Haynes NM, Trapani JA, Teng MW, Jackson JT, Cerruti L, Jane SM et al Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation. J Immunol 2002; 169: 5780-5786.
109. Wang J, Jensen M, Lin Y, Sui X, Chen E, Lindgren CG et al. Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains. Hum Gene Ther 2007; 18: 712-725.
110. Finney HM, Akbar AN, Lawson AD. Activation of resting human primary T cells with chimeric receptors: Costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCRζ chain. J Immunol 2004; 172: 104-113.
111. Imai C, Mihara K, Andreansky M, Nicholson IC, Pui CH, Geiger TL et al Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 2004; 18: 676-684.
112. Quintarelli C, Vera JF, Savoldo B, Giordano Attianese GM, Pule M, Foster A et al. Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor specific cytotoxic T lymphocytes. Blood 2007; 110: 2793-2802.
113. Hsu C, Hughes MS, Zheng Z, Bray RB, Rosenberg SA, Morgan RA. Primary human T lymphocytes engineered with a codon-optimized IL-15 gene resist cytokine withdrawal-induced apoptosis and persist long-term in the absence of exogenous cytokine. J Immunol 2005; 175: 7226-7234.
114. Hsu C, Jones SA, Cohen CJ, Zheng Z, Kerstann K, Zhou J et al. Cytokine-independent growth and clonal expansion of a primary human CD8+ T-cell clone following retroviral transduction with the IL-15 gene. Blood 2007; 109: 5168-5177.
115. Liu K, Rosenberg SA. Transduction of an IL-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity. J Immunol 2001; 167: 6356-6365.
116. Kasid A, Morecki S, Aebersold P, Cornetta K, Culver K, Freeman S et al. Human gene transfer: Characterization of human tumor-infiltrating lymphocytes as vehicles for retroviral-mediated gene transfer in man. Proc Natl Acad Sci USA 1990; 87: 473-477.
117. Cooper LJ, Al-Kadhimi Z, Serrano LM, Pfeiffer T, Olivares S, Castro A et al. Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1. Blood 2004; 105: 1622-1631.
118. Rossig C, Bollard CM, Nuchtern JG, Rooney CM, Brenner MK. Epstein-Barr virus-speci.c human T lymphocytes expressing antitumor chimeric T-cell receptors: Potential for improved immunotherapy. Blood 2002; 99 2009-2016.
119. Kershaw MH, Westwood JA, Hwu P. Dual-specific T cells combine proliferation and antitumor activity. Nat Biotechnol 2002; 20 1221-1227.
120. Gough M, Crittenden M, Thanarajasingam U, Sanchez-Perez L, Thompson J, Jevremovie D et al. Gene therapy to manipulate effector T cell trafficking to tumors for immunotherapy. J Immunol 2005; 174 5766-5773.
121. Bollard CM, Rossig C, Calonge MJ, Huls MH, Wagner HJ, Massague J et al. Adapting a transforming growth factor β-related tumor protection strategy to enhance antitumor immunity. Blood 2002; 99: 3179-3187.
122. Lacuesta K, Buza E, Hauser H, Granville L, Pule M, Corboy G et al. Assessing the safety of cytotoxic T lymphocytes transduced with a dominant negative transforming growth factor-β receptor. J Immunother 2006; 29: 250-260.
123. Dotti G, Savoldo B, Pule M, Straathof KC, Biagi E, Yvon E et al. Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis. Blood 2005; 105: 4677-4684.
124. Sato T, Neschadim A, Konrad M, Fowler DH, Lavie A, Medin JA. Engineered human tmpk/AZT as a novel enzyme/prodrug axis for suicide gene therapy. Mol Ther 2007; 15: 962-970.
125. Berger C, Blau CA, Huang ML, Iuliucci JD, Dalgarno DC, Gaschet J et al. Pharmacologically regulated Fas-mediated death of adoptively transferred T cells in a nonhuman primate model. Blood 2004; 103: 1261-1269.
126. Straathof KC, Pule MA, Yotnda P, Dotti G, Vanin EF, Brenner MK et al An inducible caspase 9 safety switch for T-cell therapy. Blood 2005; 105: 4247-4254.
127. Lupton SD, Brunton LL, Kalberg VA, Overell RW. Dominant positive and negative selection using a hygromycin phosphotransferase-thymidine kinase fusion gene. Mol Cell Biol 1991; 11: 3374-3378.
128. van Meerten T, Claessen MJ, Hagenbeek A, Ebeling SB. The CD20/alphaCD20 'suicide' system: Novel vectors with improved safety and expression profiles and efficient elimination of CD20-transgenic T cells. Gene Ther 2006; 13: 789-797.
129. Sangiolo D, Lesnikova M, Nash RA, Jensen MC, Nikitine A, Kiem HP et al. Lentiviral vector conferring resistance to mycophenolate mofetil and sensitivity to ganciclovir for in vivo T-cell selection. Gene Ther 2007; 14: 1549-1554.
130. Rettig MP, Ritchey JK, Meyerrose TE, Haug JS, DiPersio JF. Transduction and selection of human T cells with novel CD34/thymidine kinase chimeric suicide genes for the treatment of graft-versus-host disease. Mol Ther 2003; 8: 29-41.
131. O'Brien TA, Tuong DT, Basso LM, McIvor RS, Orchard PJ. Coexpression of the uracil phosphoribosyltransferase gene with a chimeric human nerve growth factor receptor/cytosine deaminase fusion gene, using a single retroviral vector, augments cytotoxicity of transduced human T cells exposed to 5-fluorocytosine. Hum Gene Ther 2006; 17: 518-530.
132. Orchard PJ, Blazar BR, Burger S, Levine B, Basso L, Nelson DM et al Clinical-scale selection of anti-CD3/CD28-activated T cells after transduction with a retroviral vector expressing herpes simplex virus thymidine kinase and truncated nerve growth factor receptor. Hum Gene Ther 2002; 13: 979-988.
133. Tey SK, Dotti G, Rooney CM, Heslop HE, Brenner MK. Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol Blood Marrow Transplant 2007; 13: 913-924.
134. Bonini C, Ciceri F, Marktel S, Bordignon C. Suicide-gene-transduced T-cells for the regulation of the graft-versus-leukemia effect. Vox Sang 1998; 74 (Suppl 2): 341-343.
135. Traversari C, Marktel S, Magnani Z, Mangia P, Russo V, Ciceri F et al The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies. Blood 2007; 109: 4708-4715.
136. Bonini C, Ferrari G, Verzeletti S, Servida P, Zappone E, Ruggieri L et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 1997; 276: 1719-1724.
137. Singh H, Serrano LM, Pfeiffer T, Olivares S, McNamara G, Smith DD et al. Combining adoptive cellular and immunocytokine therapies to improve treatment of B-lineage malignancy. Cancer Res 2007; 67 2872-2880.
138. Schultze JL, Anderson KC, Gilleece MH, Gribben JG, Nadler LM. A pilot study of combined immunotherapy with autologous adoptive tumour-specific T-cell transfer, vaccination with CD40-activated malignant B cells and interleukin 2. Br J Haematol 2001; 113: 455-460.
139. Rapoport AP, Stadtmauer EA, Aqui N, Badros A, Cotte J, Chrisley L et al. Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat Med 2005; 11: 1230-1237.
140. Tran CA, Burton L, Russom D, Wagner JR, Jensen MC, Forman SJ et al Manufacturing of large numbers of patient-specific T cells for adoptive immunotherapy: An approach to improving product safety, composition, and production capacity. J Immunother (1997) 2007; 30: 644-654.